These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3287837)

  • 1. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
    Carlson LA; Rosenhamer G
    Acta Med Scand; 1988; 223(5):405-18. PubMed ID: 3287837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.
    Research Committee of the Scottish Society of Physicians
    Br Med J; 1971 Dec; 4(5790):775-84. PubMed ID: 4943606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.
    Carlson LA; Danielson M; Ekberg I; Klintemar B; Rosenhamer G
    Atherosclerosis; 1977 Sep; 28(1):81-6. PubMed ID: 911371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid lowering and ischaemic heart disease.
    Oliver MF
    Acta Med Scand Suppl; 1981; 651():285-93. PubMed ID: 6948505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin.
    Stamler J
    Adv Exp Med Biol; 1977; 82():52-75. PubMed ID: 335823
    [No Abstract]   [Full Text] [Related]  

  • 6. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.
    Lancet; 1980 Aug; 2(8191):379-85. PubMed ID: 6105515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.
    Br Med J; 1971 Dec; 4(5790):767-75. PubMed ID: 4943605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will serum lipid lowering treatment reduce the incidence of coronary heart disease?
    Vessby B; Lithell H; Boberg J
    Artery; 1981; 9(5):372-81. PubMed ID: 7032466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.
    Lancet; 1984 Sep; 2(8403):600-4. PubMed ID: 6147641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
    Rabkin SW; Hayden M; Frohlich J
    Atherosclerosis; 1988 Oct; 73(2-3):233-40. PubMed ID: 3056431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man.
    Cohn K; Sakai FJ; Langston MF
    Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofibrate and niacin in coronary heart disease.
    JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
    Wilke H; Frahm H
    Dtsch Med Wochenschr; 1976 Mar; 101(11):401-5. PubMed ID: 1253701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Lipid-lowering drugs after myocardial infarction.
    Lancet; 1975 Mar; 1(7905):501-2. PubMed ID: 46964
    [No Abstract]   [Full Text] [Related]  

  • 17. [Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].
    Kaffarnik H; Schneider J; Haase W
    Dtsch Med Wochenschr; 1975 Nov; 100(48):2486-8. PubMed ID: 1104303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum lipid precursors of coronary heart disease.
    Kannel WB; Garcia MJ; McNamara PM; Pearson G
    Hum Pathol; 1971 Mar; 2(1):129-51. PubMed ID: 5095238
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined procetofene--nicotinic acid therapy in treatment of hypertriglyceridaemia.
    Rössner S; Olsson AG
    Atherosclerosis; 1980 Apr; 35(4):413-7. PubMed ID: 7378121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.